IDEAYA completes darovasertib NDA, halts Phase 3 OptimUM-010 for enrollment issuesNov 3Quarterly updateAlector, Inc.Allogene Therapeutics
Allogene reports Q2 2026 results, cites ALPHA3 futility data and FDA designations for cema-celAug 12Quarterly updateAllogene Therapeutics